Current Report Filing (8-k)
14 Novembro 2022 - 6:32PM
Edgar (US Regulatory)
0001293310
false
0001293310
2022-11-14
2022-11-14
0001293310
dei:FormerAddressMember
2022-11-14
2022-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14,
2022
Humanigen, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35798 |
|
77-0557236 |
(State or other Jurisdiction of
Incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.)
|
830 Morris Turnpike, 4th Floor
Short Hills, NJ 07078
(Address of principal executive offices, including zip code)
(973) 200-3100
(Registrant’s telephone number, including area code)
533 Airport Boulevard, Suite 400
Burlingame, CA 94010
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
HGEN |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of
the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
On November 14,
2022, Humanigen, Inc. (the “Company”) issued a press release regarding the Company’s financial results for its three
and nine months ended September 30, 2022 and providing a corporate update. A copy of the press release is attached to this report as Exhibit
99.1 and incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Humanigen, Inc. |
|
|
|
By: |
/s/ Cameron Durrant |
|
|
|
Name: Cameron Durrant
Title: Chairman of the Board and Chief Executive Officer |
Dated: November 14, 2022
Humanigen (NASDAQ:HGEN)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Humanigen (NASDAQ:HGEN)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024